Biomimetic dual-responsive bioengineered nanotheranostics for intracellular cascade-synthesizing chemo-drugs and

Xin Zhang1, Xinglin Zhu1, Yuan He2

  • 1College of Materials, Xiamen University, Xiamen, 361005, China. houzhenqing@xmu.edu.cn.

Insights

This study developed red blood cell-cloaked nanotheranostics that convert nontoxic molecules into chemotherapy drugs within tumor cells. This approach enables intracellular cascade-synthesizing chemotherapy for enhanced oncotherapy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Tumor microenvironment (TME)-responsive chemotherapy is crucial for cancer treatment.
  • Developing strategies to convert nontoxic molecules into chemotherapeutics within the TME remains a significant challenge.

Purpose of the Study:

  • To engineer a dual-responsive nanotheranostics system for intracellular chemo-drug synthesis and oncotherapy.
  • To utilize red blood cell membranes (RBCs) for biomimetic cloaking and targeted delivery.

Main Methods:

  • Supramolecular co-assembly of 1,5-dihydroxynaphthalene (DHN) and indocyanine green (ICG) into nanotheranostics.
  • Surface cloaking of nanotheranostics with RBC membranes.
  • Dual-stimulation triggered (NIR laser and acidic lysosomes) disassembly and drug release.
  • Photodynamic generation of singlet oxygen (¹O₂) and subsequent oxidation of DHN to juglone.

Main Results:

  • The developed nanotheranostics exhibited a suitable diameter, core-shell structure, high drug payload, and stability.
  • Efficient accumulation and internalization into tumor cells were observed.
  • On-demand drug release and intracellular cascade-synthesis of the toxic drug juglone from DHN were achieved.
  • Synergistic photodynamic-chemotherapy was demonstrated, with reduced side effects on normal cells.

Conclusions:

  • Red blood cell-cloaked nanotheranostics offer a promising platform for intracellular chemo-drug synthesis.
  • This strategy facilitates efficient oncotherapy by generating toxic drugs specifically within cancer cells.
  • The dual-responsive system enables targeted drug release and synergistic therapeutic effects.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K